4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-25-006296
CHIEF FINANCIAL OFFICER sold 3,250 shares at $20.41 ($66,327)
- CHIEF FINANCIAL OFFICER acquired 3,250 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Hohl Benjamin · CHIEF FINANCIAL OFFICER
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-02-27 | Exercise or conversion : show line 1 in the form 10b5-1 | +3,250 | $2.48 | $8,060 | 16,250 | D |
| 2025-02-27 | Sale : show line 2 in the form 10b5-1 | −3,250 | $20.41 | $66,327 | 13,000 | D |
| Open-market sales · 3,250 sh · avg $20.41 · $66,327 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2025-02-27 | Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) | −3,250 | 142,806 | D |
Loading xslF345X05/form4-03042025_010306.xml…